专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2007093621A1 CYCLIC SULFONES USEFUL AS BACE INHIBITORS 审中-公开
标题翻译：循环硫磺有效用作BACE抑制剂
公开(公告)号：WO2007093621A1
公开(公告)日：2007-08-23
申请号：PCT/EP2007/051454
申请日：2007-02-14
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , RUEEGER, Heinrich , MCCARTHY, Clive , MOEBITZ, Henrik , RONDEAU, Jean-Michel , TINTELNOT-BLOMLEY, Marina
发明人： RUEEGER, Heinrich , MCCARTHY, Clive , MOEBITZ, Henrik , RONDEAU, Jean-Michel , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D335/02
CPC分类号： C07D335/02 , C07D409/12 , C07D413/10 , C07D413/12 , C07D417/12
摘要： The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
摘要翻译：本发明涉及式（I）的新型杂环化合物，其中所有变量如本说明书中所定义，游离碱形式或酸加成盐形式，其制备方法，用作药物和药物包括他们。

12. 发明申请

WO2011080176A1 PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS 审中-公开
标题翻译：吡嗪衍生物及其在治疗神经疾病中的应用
公开(公告)号：WO2011080176A1
公开(公告)日：2011-07-07
申请号：PCT/EP2010/070502
申请日：2010-12-22
申请人： NOVARTIS AG , TINTELNOT-BLOMLEY, Marina , VEENSTRA, Siem Jacob
发明人： TINTELNOT-BLOMLEY, Marina , VEENSTRA, Siem Jacob
IPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , A61K31/497 , A61P25/28
CPC分类号： C07D401/12 , A61K31/497 , C07D401/14 , C07D403/12
摘要： The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
摘要翻译：本发明涉及式（I）的新型杂环化合物，其中所有变量如说明书中所定义，以游离形式或盐形式，其制备，其医疗用途和包含它们的药物。

13. 发明申请

WO2005014517A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF 审中-公开
标题翻译：新二苯并[B，F] OXEPINE-10-羧酰胺及其药物用途
公开(公告)号：WO2005014517A2
公开(公告)日：2005-02-17
申请号：PCT/EP2004/008283
申请日：2004-07-23
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , AUBERSON, Yves , BETSCHART, Claudia , FLOHR, Stefanie , GLATTHAR, Ralf , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina , TROXLER, Thomas, J. , VANGREVELINGHE, Eric , VEENSTRA, Siem, Jacob
发明人： AUBERSON, Yves , BETSCHART, Claudia , FLOHR, Stefanie , GLATTHAR, Ralf , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina , TROXLER, Thomas, J. , VANGREVELINGHE, Eric , VEENSTRA, Siem, Jacob
IPC分类号： C07C61/00
CPC分类号： C07D405/12 , C07C235/82 , C07C2603/32 , C07D313/14 , C07D407/12 , C07D413/12 , C07D453/02 , C07D491/04
摘要： The present invention pertains to compounds of formula (I) wherein X is O, NH, N(C 1-4 )alkyl, CO or CHOH, Y is CH or N, A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached, R 1 is hydrogen or (C 1-4 )alkyl, R 2 is optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl or heteroaryl, R 3 is CH(R e )CONR a R b or (CH 2 ) n NR c ,R d , n is 0, 1 or 2, R a , R b , R c and R d , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, (C 7-9 )bicycloalkyl, 1-aza-(C 7-9 )bicycloalkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl, heteroaryl(C 1-4 )alkyl or heterocyclyl, or R a , R b , R c and R d , together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group, R e is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 3-7 )cycloalkyl or (C 3-7 )cycloalkyl(C 1-4 )alkyl, and R 4 , R 5 , R 6 , R 7 , R 8 and R 9 , independently, are hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 1-4 )alkyl-SO 2 , cyano, nitro or halogen; to a process for the preparation of such compounds of formula (I), their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula (I).
摘要翻译：本发明涉及式（I）化合物，其中X是O，NH，N（C 1-4）烷基，CO或CHOH，Y是CH或N，A和B各自是氢或一起形成第二键碳原子，R 1是氢或（C 1-4）烷基，R 2是任选取代的（C 1-8）烷基，（C 3-7）环烷基，（C 3-7）环烷基（C 1-4）烷基，芳基或杂芳基，R3是CH（Re）CONRaRb或（CH2）nNRc，Rd，n是0,1或2，Ra，Rb，Rc和Rd独立地是氢或任选取代的（C 1-8）烷基，（ C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，（C7-9）双环烷基，1-氮杂 - （C7-9）双环烷基，芳基，芳基（C1-4）烷基，杂芳基，杂芳基（C 1-4）烷基或杂环基，或R a，R b，R c和R d与它们所连接的氮一起形成任选取代的吡咯烷基，哌啶子基，吗啉代或哌嗪基，Re是（C 1-8）烷基，（C 1-4）烷氧基（C 1-4）烷基，（C 3-7）环烷基或（C 3-7）环烷基（C 1-4）烷基，R 4，R 5，R 6，R 7，R 8和R 9独立地为氢，（C1-4 ）烷基，（C 1-4）烷氧基，（C 1-4）烷基-SO 2，氰基，硝基或卤素; 制备这种式（I）化合物的方法，它们作为药物的用途，特别是用于治疗与β-淀粉样蛋白生成和/或聚集相关的神经和血管疾病，以及包含这些化合物的药物组合物和组合的式（I）化合物。

14. 发明申请

WO2009021957A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2009021957A2
公开(公告)日：2009-02-19
申请号：PCT/EP2008/060598
申请日：2008-08-12
申请人： NOVARTIS AG , HINTERMANN, Samuel , HURTH, Konstanze , TINTELNOT-BLOMLEY, Marina
发明人： HINTERMANN, Samuel , HURTH, Konstanze , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D471/04 , C07D491/04 , A61K31/4745 , A61P25/00
CPC分类号： C07D471/04 , C07D491/04
摘要： The invention relates to compound of the formula (I), in which R 1 represents an optionally substituted aryl group or an optionally substituted heteroaryl group; R 2 represents hydrogen or a substituent different from hydrogen; R 3 represents an optionally substituted aryl group, cycloalkyl group, heteroaryl group, heterocyclyl group; X 1 represents O, S, NR 4 , CR 4 2 ; X 2 represents O, S, NR 4 , CR 4 2 ; X 3 represents 0O S, NR 4 , CR 4 2 ; X 4 represents O, S, NR 4 , CR 4 2 ; R 4 represents hydrogen or a substituent different from hydrogen; R 5 represents hydrogen or alkyl; Y represents O or S; m represents 0, 1, 2 or 3; n represents 0, 1, 2 or 3 in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
摘要翻译：本发明涉及式（I）化合物，其中R 1表示任选取代的芳基或任选取代的杂芳基; R2代表氢或不同于氢的取代基; R 3表示任选取代的芳基，环烷基，杂芳基，杂环基; X1表示O，S，NR4，CR4 2; X2表示O，S，NR4，CR4 2; X3表示0S，NR4，CR4 2; X 4表示O，S，NR 4，CR 4 2; R4表示氢或不同于氢的取代基; R5代表氢或烷基; Y表示O或S; m表示0,1,2或3; n表示游离碱形式或酸加成盐形式的0,1,2或3; 作为其制备，用作药物和包含它的药物。

15. 发明申请

WO2009021961A1 PYRAZOLOQUINOLINE AND PYRAZOLONAPHTHYRIDINE DERIVATIVES AS GABA ALPHA LIGANDS 审中-公开
标题翻译：吡唑并喹啉和吡唑并吡啶衍生物作为GABA ALPHA配体
公开(公告)号：WO2009021961A1
公开(公告)日：2009-02-19
申请号：PCT/EP2008/060603
申请日：2008-08-12
申请人： NOVARTIS AG , HINTERMANN, Samuel , HURTH, Konstanze , NOZULAK, Joachim , TINTELNOT-BLOMLEY, Marina
发明人： HINTERMANN, Samuel , HURTH, Konstanze , NOZULAK, Joachim , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D471/04 , C07D471/14 , A61K31/4745 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/28
CPC分类号： C07D471/04 , C07D471/14
摘要： The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
摘要翻译：本发明涉及式（I）化合物，其中取代基如说明书中所定义; 游离碱形式或酸加成盐形式; 作为其制备，用作药物和包含它的药物。

16. 发明申请

WO2007140980A1 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS 审中-公开
标题翻译：吡咯烷衍生物有效用作BACE抑制剂
公开(公告)号：WO2007140980A1
公开(公告)日：2007-12-13
申请号：PCT/EP2007/004959
申请日：2007-06-04
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , ROGEL, Olivier , RONDEAU, Jean-Michel , RUEEGER, Heinrich , SIMIC, Oliver , SIROCKIN, Finton , TINTELNOT-BLOMLEY, Marina
发明人： ROGEL, Olivier , RONDEAU, Jean-Michel , RUEEGER, Heinrich , SIMIC, Oliver , SIROCKIN, Finton , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D215/48 , A61K31/47 , A61P25/28
CPC分类号： C07D215/48
摘要： Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class in the treatment of a disease that depends on the activity of beta- secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as defined in the specification.
摘要翻译：新型3-单，3,4-二和3,4,4-三取代的吡咯烷化合物，用于诊断和治疗温血动物，特别是用于治疗疾病的化合物（=无序），其取决于β-分泌酶的活性和/或β-淀粉样蛋白的产生，并随后聚集成低聚物和原纤维; 使用该类化合物来制备用于治疗依赖于β-分泌酶的活性和/或产生β-淀粉样蛋白的疾病的药物制剂并随后聚集成低聚物和原纤维; 使用该类化合物治疗依赖于β-分泌酶活性和/或产生β-淀粉样蛋白的疾病，随后聚集成低聚物和原纤维; 包含所述取代的吡咯烷化合物的药物制剂和/或包括施用所述取代的吡咯烷化合物的治疗方法。取代的吡咯烷化合物特别是式（I），其中取代基如说明书中所定义。

17. 发明申请

WO2006074940A3 MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS 审中-公开
公开(公告)号：WO2006074940A3
公开(公告)日：2006-07-20
申请号：PCT/EP2006/000265
申请日：2006-01-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LERCHNER, Andreas , MACHAUER, Rainer , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina
发明人： LERCHNER, Andreas , MACHAUER, Rainer , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D245/06 , C07D281/00 , A61P25/28 , A61K31/395
摘要： The invention relates to novel macrocyclic compounds of the formula in which R 1 , R 3 , V 1 , V 2 , X 1 , X 2 , Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

18. 发明申请

WO2005003106A1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF 审中-公开
标题翻译：具有ASPARTIC PROTEASE抑制活性的药物化合物及其药物用途
公开(公告)号：WO2005003106A1
公开(公告)日：2005-01-13
申请号：PCT/EP2004/007247
申请日：2004-07-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BETSCHART, Claudia , TINTELNOT-BLOMLEY, Marina
发明人： BETSCHART, Claudia , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D273/02
CPC分类号： C07D285/00 , A61K31/33 , C07D273/02 , C07D291/08
摘要： The present invention relates to macrocyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 ) cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 ) alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-8 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S0 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
摘要翻译：本发明涉及式（I）的大环化合物，其中R1是（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷硫基（C 1-4）烷基，（C 1-6）烯基，（C 3-7）环烷基，（C 3-7）环烷基（C 1-4）烷基，哌啶基或吡咯烷基，R 2和R 4独立地为氢或任选取代（C 1-8）烷基，（C 3-7）环烷基，（C 3-7）环烷基（C 1-4）烷基，芳基，芳基（C 1-4）烷基，杂芳基或杂芳基 R4与其连接的氮一起形成任选取代的哌啶子基，吡咯烷基，吗啉代或哌嗪基，R 3是氢或（C 1-4）烷基，X 1是CH 2，X 2是CH 2，O，S，CO， CO，OCO，NHCO，CONH或NR，R为氢或（C1-4）烷基，Y为（C1-8）亚烷基或（C1-8）亚烷基氧基（C1-6）亚烷基，（C1-8）或（C 1-8）亚烯基氧基（C 1-6）亚烷基，Ar是任选被羟基或卤素单独二或三取代的苯环，其中X 1和X 2在每个ot 而且Z为CO，AA为天然或非天然的α-氨基酸，n为0或1，或Z为SO 2，AA为任选取代的亚乙基羰基（衍生自天然或非天然的α-氨基酸通过亚甲基取代氮），n为1; 制备这些化合物的方法; 药物组合物及其组合物; 以及它们用于治疗与β-淀粉样蛋白生成和/或聚集相关的神经和血管疾病的用途。

19. 发明申请

WO2015181747A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS 审中-公开
标题翻译：新型吡咯并吡啶衍生物及其作为MALT1抑制剂的用途
公开(公告)号：WO2015181747A1
公开(公告)日：2015-12-03
申请号：PCT/IB2015/053975
申请日：2015-05-27
申请人： NOVARTIS AG , PISSOT SOLDERMANN, Carole , QUANCARD, Jean , SCHLAPBACH, Achim , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina , ZOLLER, Thomas
发明人： PISSOT SOLDERMANN, Carole , QUANCARD, Jean , SCHLAPBACH, Achim , SIMIC, Oliver , TINTELNOT-BLOMLEY, Marina , ZOLLER, Thomas
IPC分类号： C07D487/04 , A61K31/519 , A61P29/00 , A61P35/00 , A61P37/00
CPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C 1 -C 3 alkyl optionally substituted by halogen; R2 is C 1 -C 6 alkyl optionally substituted one or more times by C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxyl, N,N-di-C 1 -C 6 alkyl amino, N-mono-C 1 -C 6 alkyl amino, O-Rg, Rg, phenyl, or by C 1 -C 6 alkoxy wherein said alkoxy again may optionally be substituted by C 1 -C 6 alkoxy, N,N-di-C 1 -C 6 alkyl amino, Rg or phenyl; C 3 -C 6 cycloalkyl optionally substituted by C 1 -C 6 alkyl, N,N-di-C 1 -C 6 alkyl amino or C 1 -C 6 alkoxy-C 1 -C 6 alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C 1 -C 6 alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C 1 -C 6 alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C 1 -C 6 alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
摘要翻译：本发明描述了式（I）的新的吡唑并嘧啶衍生物或其药学上可接受的盐; （I）其中，R 1为卤素，氰基或任选被卤素取代的C 1 -C 3烷基; R2是任选被C 1 -C 6烷基，C 2 -C 6烯基，羟基，N，N-二-C 1 -C 6烷基氨基，N-单-C 1 -C 6烷基氨基，O-R g，R g，苯基，或C 1 -C 6烷氧基，其中所述烷氧基再次可任选被C 1 -C 6烷氧基，N，N-二-C 1烷基氨基，R g或苯基取代; 任选地被C 1 -C 6烷基，N，N-二-C 1 -C 6烷基氨基或C 1 -C 6烷氧基-C 1 -C 6烷基取代的C 3 -C 6环烷基和/或所述任选取代基中的两个与它们所键合的原子一起形成环状或包含1〜2个O原子的螺环4-6元饱和杂环; 任选被C 1 -C 6烷氧基取代的苯基; 具有1至3个选自N和O的杂原子的5-6元杂芳基环，所述环任选被可被氨基或羟基任选取代的C 1 -C 6烷基取代; RG; 或N，N-二-C 1 -C 6烷基氨基羰基; R为独立地被R a取代两次或更多次的苯基，R 2独立地取代一次或多次的2-吡啶基，R c独立地取代一次或多次的3-吡啶基，或被Rd独立地取代一次或多次的4-吡啶基; 其通常与MALT1蛋白水解和/或自发蛋白水解活性相互作用，特别是可能抑制所述活性。本发明还描述了所述新的吡唑并嘧啶衍生物的合成，它们作为药物的用途，特别是通过与MALT1蛋白水解和/或自身蛋白水解活性的相互作用。

20. 发明申请

WO2013008162A1 NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE 审中-公开
标题翻译：新型三氟甲基 - 氧杂唑衍生物及其在治疗疾病中的应用
公开(公告)号：WO2013008162A1
公开(公告)日：2013-01-17
申请号：PCT/IB2012/053470
申请日：2012-07-06
申请人： NOVARTIS AG , HEBACH, Christina , JOLY, Emilie , KALLEN, Joerg , TERNOIS, James Gilbert , TINTELNOT-BLOMLEY, Marina
发明人： HEBACH, Christina , JOLY, Emilie , KALLEN, Joerg , TERNOIS, James Gilbert , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D271/06 , C07D413/10 , C07D413/12 , A61K31/4245 , A61P25/28 , A61P3/00
CPC分类号： C07D271/06 , A61K31/4245 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D413/10 , C07D413/12
摘要： The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.
摘要翻译：本发明涉及式（I）的新型三唑 - 恶二唑衍生物及其药学上可接受的盐，（I）其中所有变量如本说明书中所定义，其药物组合物，其药物组合及其作为药物的用途，特别是通过抑制HDAC4治疗神经变性，肌肉萎缩或代谢综合征。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式